Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 6,500 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. The trade was a 12.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Edwards Lifesciences Trading Up 0.3 %

EW stock opened at $76.23 on Friday. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market cap of $44.96 billion, a P/E ratio of 11.00, a P/E/G ratio of 3.64 and a beta of 1.10. The business’s 50 day moving average is $72.58 and its 200-day moving average is $69.41. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EW. Evercore ISI reduced their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday. Piper Sandler boosted their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday. Morgan Stanley boosted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Robert W. Baird reduced their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Finally, Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and an average price target of $79.95.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company’s stock worth $2,458,601,000 after acquiring an additional 1,678,154 shares in the last quarter. State Street Corp boosted its holdings in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after acquiring an additional 256,538 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Edwards Lifesciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company’s stock worth $1,007,520,000 after acquiring an additional 126,194 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in shares of Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock worth $723,664,000 after acquiring an additional 696,965 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.